Semaglutide vs Tirzepatide: The Honest Comparison

The comparison at a glance

Trial figures are average percentage of body weight lost at the trial endpoint on the highest maintenance doses; individual results vary substantially in both directions.

One receptor vs two: why tirzepatide pulls ahead

Semaglutide activates the GLP-1 receptor, which slows gastric emptying, moderates appetite signaling, and improves insulin response. Tirzepatide activates GLP-1 and GIP receptors simultaneously. The dual action appears to amplify the appetite and metabolic effects, which is the leading explanation for the roughly six-point gap in average trial results.

The mechanism difference is not academic; it shows up in the distribution of outcomes, not just the average. In SURMOUNT-1, a substantially larger share of tirzepatide patients reached the 20%-plus loss tier than semaglutide patients do in comparable trials. For context on where the field is heading, retatrutide, a triple-agonist, posted 24.2% in phase 2, but it remains unapproved and available only inside clinical trials, so it is not a purchasing option.

The dual mechanism carries a second practical implication: dose headroom. Tirzepatide's range spans 2.5 mg to 15 mg, giving prescribers several maintenance levels to work with, against semaglutide's ceiling of 2.4 mg. In practice, a disappointing tirzepatide response has more adjustment room left before a molecule switch becomes the conversation, while semaglutide reaches its maximum earlier.

Side effects and tolerability: mostly a tie

Both molecules share the same dominant side effect profile: gastrointestinal effects, nausea, constipation, diarrhea, and vomiting, concentrated during dose escalation and generally easing at stable doses. Both use gradual titration specifically to manage this, semaglutide over roughly 16 weeks to 2.4 mg, tirzepatide stepping from 2.5 mg toward 15 mg.

Neither molecule is appropriate for everyone; personal and family medical history changes the calculus, which is why a licensed provider's evaluation is the required step, not an optional one. Discontinuation rates for adverse events were broadly similar in trials. Practical upshot: tolerability rarely decides between the two molecules in advance. Cost and target outcome decide, and side effect response sometimes forces a switch after the fact.

Practical differences do show up in the ramp itself. Semaglutide's schedule steps through five dose levels to reach 2.4 mg, typically over about sixteen weeks; tirzepatide's moves from 2.5 mg through as many as six levels toward 15 mg over a longer arc. Slower ramps mean more months at partial effect, which is worth remembering when interpreting early results on either drug: neither is expected to show its trial-average pace in the first quarter of treatment.

The price gap, channel by channel

Semaglutide is cheaper on every comparable channel, but the margin varies:

• Compounded floor: semaglutide from about $99/mo versus tirzepatide from about $199/mo, a $1,200/year gap at the entry level.
• Brand self-pay: $499 flat via NovoCare versus $349–$499 via LillyDirect vials. At maintenance doses both sit at $499, an effective tie.
• Retail list: $998–$1,349 versus $1,069–$1,086, irrelevant for anyone using the direct programs.
• Insured: $25–$50 copay either way when covered, making coverage, not molecule, the variable.

One way to collapse effectiveness and price into a single figure: cost per average percentage point of body weight lost over a year of treatment. At $499 brand pricing, tirzepatide's 20.9% average works out to roughly $285 per point per year, semaglutide's 15% to about $400. At compounded floor prices the order tightens in semaglutide's favor, roughly $80–$240 per point against $115–$260 for tirzepatide. Crude, but it explains the market's behavior: tirzepatide dominates brand self-pay decisions, while semaglutide owns the budget tier.

Detailed channel math lives in the semaglutide cost guide and tirzepatide cost guide. Note the crossover: at brand maintenance pricing, the more effective molecule costs the same $499, which has shifted many self-pay decisions toward tirzepatide.

Insurance adds the final wrinkle: formularies do not treat the two molecules symmetrically, and plenty of plans cover one while excluding the other. Since a covered copay beats any cash price, the pragmatic first step is checking both brand names against your formulary before debating averages at all.

Which one fits which situation

The decision usually resolves along these lines:

• Budget is the binding constraint: compounded semaglutide at $99–$299 is the value play, and a 13.7–15% average result is substantial by any historical standard.
• Maximum average effect matters most: tirzepatide's 20%-class results make it the default, especially at $499 brand pricing where the semaglutide discount disappears.
• Insurance covers one but not the other: take the covered one; a $25–$50 copay dominates every cash price.
• Higher starting BMI or larger total goal: the extra average points of loss compound; the brand-level Wegovy vs Zepbound comparison adds the indication-specific coverage angles.

Eligibility criteria are identical for both, BMI 30 or higher, or 27 with a comorbidity, and a licensed provider makes the final call on fit. You can check eligibility and compare both molecules' current pricing here.